This article describes a new physiology via the upregulation of FGF23 by ferric carboxymaltose (FCM) with subsequent development of hypophosphatemia. It provides a degree of caution with the long-term use of this formulation of IV iron but aptly points out that clinically significant hypophosphatemia is rare.
What this should do is stimulate long-term evaluation of the safety of this widely used product. The paper also appropriately points out the need to monitor phosphorus levels as a routine part of FCM’s use.
The physiology is beautifully described and the reader will know much more about renal physiology after reading the manuscript.
– Michael Auerbach